Mark Merchant

机构：Revolution Medicines (United States) · ORCID：0000-0003-0690-8581

发表论文 380 篇 · 总被引 10658 次 · h-index 48

代表论文

PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models (2024 · Journal of Medicinal Chemistry · 被引 33)
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer (2024 · Cancer · 被引 8)
Quantitative Assessment of the Target Engagement of a KRAS G12C Inhibitor in Formalin-Fixed Paraffin-Embedded Tumor Tissues Using Immunoaffinity Capture 2D-LC-MS/MS (2025 · Analytical Chemistry · 被引 1)
Data from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy (2025 · 被引 1)
Abstract 6849: RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy (2025 · Cancer Research · 被引 1)
RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy (2024 · Research Square · 被引 1)